CARDIFF ONCOLOGY, INC. Increase Decrease In Operating Lease Liability
CARDIFF ONCOLOGY, INC. (CRDF) reported Increase Decrease In Operating Lease Liability of -$375.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$189.00K.
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$186.00K.
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$178.00K.
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$175.00K.
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2025 was -$691.00K.
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2024 was -$626.00K.
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2023 was -$566.00K.
- CARDIFF ONCOLOGY, INC. increase decrease in operating lease liability for fiscal 2022 was -$404.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$375.00K 10-Q · filed 2026-08-11 | -$553.00K derived: sum of 3 quarters · filed 2026-08-11 | -$728.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$186.00K 10-Q · filed 2026-05-14 | -$364.00K derived: sum of 2 quarters · filed 2026-05-14 | -$539.00K derived: sum of 3 quarters · filed 2026-05-14 | -$710.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$353.00K derived: sum of 2 quarters · filed 2026-02-24 | -$524.00K derived: sum of 3 quarters · filed 2026-08-11 | -$691.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | -$175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$346.00K derived: sum of 2 quarters · filed 2026-08-11 | -$513.00K 10-Q · filed 2025-11-06 | -$676.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$338.00K 10-Q · filed 2026-08-11 | -$501.00K derived: sum of 3 quarters · filed 2026-08-11 | -$658.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$167.00K 10-Q · filed 2026-05-14 | -$330.00K derived: sum of 2 quarters · filed 2026-05-14 | -$487.00K derived: sum of 3 quarters · filed 2026-05-14 | -$641.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$320.00K derived: sum of 2 quarters · filed 2026-02-24 | -$474.00K derived: sum of 3 quarters · filed 2026-02-24 | -$626.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | -$157.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$311.00K derived: sum of 2 quarters · filed 2025-11-06 | -$463.00K 10-Q · filed 2025-11-06 | -$609.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$154.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$306.00K 10-Q · filed 2025-07-29 | -$452.00K derived: sum of 3 quarters · filed 2025-07-29 | -$593.00K derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | -$152.00K 10-Q · filed 2025-05-08 | -$298.00K derived: sum of 2 quarters · filed 2025-05-08 | -$439.00K derived: sum of 3 quarters · filed 2025-05-08 | -$580.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$287.00K derived: sum of 2 quarters · filed 2025-02-27 | -$428.00K derived: sum of 3 quarters · filed 2025-02-27 | -$566.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | -$141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$282.00K derived: sum of 2 quarters · filed 2024-11-07 | -$420.00K 10-Q · filed 2024-11-07 | -$553.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$141.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$279.00K 10-Q · filed 2024-08-08 | -$412.00K derived: sum of 3 quarters · filed 2024-08-08 | -$540.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$138.00K 10-Q · filed 2024-05-02 | -$271.00K derived: sum of 2 quarters · filed 2024-05-02 | -$399.00K derived: sum of 3 quarters · filed 2024-05-02 | -$526.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$261.00K derived: sum of 2 quarters · filed 2024-02-29 | -$388.00K derived: sum of 3 quarters · filed 2024-02-29 | -$404.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | -$128.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$255.00K derived: sum of 2 quarters · filed 2023-11-02 | -$271.00K 10-Q · filed 2023-11-02 | -$437.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$143.00K 10-Q · filed 2023-08-09 | -$309.00K derived: sum of 3 quarters · filed 2023-08-09 | -$493.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$16.00K 10-Q · filed 2023-05-04 | -$182.00K derived: sum of 2 quarters · filed 2023-05-04 | -$366.00K derived: sum of 3 quarters · filed 2023-05-04 | |
| 2021-12-31 | -$166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$350.00K derived: sum of 2 quarters · filed 2023-03-02 | -$811.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$184.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$645.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$461.00K 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | -$857.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |